Oncoproteins & Receptor Signaling
8
Terms
Term Reference
8 terms| Term | Description | |
|---|---|---|
| BCR-ABL BCR-ABL Fusion Oncoprotein | Philadelphia chromosome fusion defining CML–imatinib's success proved the precision oncology paradigm. | |
| BRAF B-Raf Proto-Oncogene | MAPK pathway kinase mutated in ~50% of melanomas–BRAF-MEK interaction is therapeutically targetable. | |
| EGFR Epidermal Growth Factor Receptor | Receptor tyrosine kinase driving NSCLC–dimerization and activation state are key to signaling. | |
| HER2-HER3 Dimerization ErbB2-ErbB3 Heterodimer | Most potent HER family signaling dimer. FRET detection of dimerization could predict therapy response beyond HER2 expres... | |
| KRAS Kirsten Rat Sarcoma Viral Oncogene | Most commonly mutated oncogene–KRAS G12C inhibitors represent breakthrough in 'undruggable' targets. | |
| mTOR Mechanistic Target of Rapamycin | Master growth regulator downstream of Akt–therapeutic target in kidney cancer and other malignancies. | |
| PKB/Akt Protein Kinase B | Key survival kinase. FRET-detected activation (pT308) predicts prognosis in breast cancer where expression fails. | |
| PTEN Phosphatase and Tensin Homolog | Tumor suppressor opposing PI3K–PTEN loss drives Akt activation measurable by FRET. |